S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Celldex Therapeutics Prices Public Offering of Common Stock (2015/2/25)|
|Celldex Therapeutics Announces Proposed Public Offering of Common Stock (2015/2/24)|
|Celldex Therapeutics Announces Appointment to Board of Directors (2014/12/18)|
|Celldex Therapeutics Announces Upcoming Presentation at the 2015 Leerink Global Healthcare Conference (2015/2/9)|
|Celldex Therapeutics Initiates a Phase 2 Study of Glembatumumab Vedotin in Patients with Advanced Melanoma (2014/12/4)|
|Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdivo(R) in Advanced Refractory Solid Tumors (2015/1/29)|
|Celldex Reports Fourth Quarter and Year-End 2014 Results (2015/2/24)|
|Celldex Announces Exercise of Underwriters' Option to Purchase Additional Shares (2015/2/27)|
|Celldex Announces Completion of Enrollment in Phase 3 Study of Rindopepimut in Frontline Glioblastoma (2014/12/15)|
|Celldex's Rindopepimut (Rintega(R)) Receives FDA Breakthrough Therapy Designation for the Treatment of Adult Patients with EGFRvIII-positive Glioblastoma (2015/2/23)|
Click above to view more mutual fund data and stats for cldx - Celldex Therapeutics Inc.